DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 2 Bristol Myers - 1 Giovanni Caforio - 1 Joerg Reinhardt - 1 Vas Narasimhan - 1 Sandoz - 1 Paul Choi - 1 Arvinas - 1
Top related locs:
Cambridge , Massachusetts U.S Boston
Top related orgs:
Novartis - 1 Institutes - 1 Research - 1 Bristol - 1 Bristol Myers Squibb - 1 Biotech - 1 Arvinas - 1 Pfizer - 1

Search resuls for: "Arvinas"


3 mentions found


☆ Novartis lifts guidance after first-quarter results beat expectations
  + stars: | 2024-04-23 | by ( ) www.cnbc.com   time to read: +2 min
Signage is displayed on the exterior of the Novartis AG Institutes for BioMedical Research building in Cambridge, Massachusetts, U.S., on Friday, Aug. 5, 2016. Swiss drugmaker Novartis on Tuesday raised its full-year guidance after reporting better-than-expected first-quarter results. In a statement, it said 2024 net sales would likely grow by a high-single to low double-digit percentage with adjusted operating income expected to grow by a low double-digit to mid-teens percentage. It has previously predicted that adjusted operating income would increase by a "high single-digit" percentage with "mid single-digit" sales growth. Quarterly adjusted operating income gained 16% to $4.54 billion, beating an average analyst estimate of about $4.3 billion.
Persons: Bristol Myers, Giovanni Caforio, Joerg Reinhardt, Vas Narasimhan, Sandoz Organizations: Novartis, Institutes, Research, Bristol, Bristol Myers Squibb Locations: Cambridge , Massachusetts, U.S
☆ Goldman gives this innovative cancer-fighting biotech nearly 70% upside
  + stars: | 2024-02-01 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +1 min
Biotech company Arvinas could see its shares rally from a potential medium- to long-term commercial opportunity, according to Goldman Sachs. The firm initiated coverage on Arvinas with a buy rating and price target of $70. That suggests 68.7% upside potential from where shares closed Wednesday. According to analyst Paul Choi, breast cancer drug vepdegestrant (ARV-471), which is being co-developed by Arvinas and Pfizer , presents an "underappreciated" commercial opportunity. Arvinas has a "differentiated protein degrader platform that could expand several major markets," Choi wrote in a Thursday note.
Persons: Goldman Sachs, Paul Choi, Arvinas, Choi, — CNBC's Michael Bloom Organizations: Biotech, Arvinas, Pfizer
☆ Here are Thursday's biggest analyst calls: Nvidia, Apple, Microsoft, Qualcomm, Target, AT&T, Tesla & more
  + stars: | 2024-02-01 | by ( Michael Bloom | ) www.cnbc.com   time to read: +7 min
Here are Thursday's biggest calls on Wall Street: Morgan Stanley downgrades ZoomInfo to equal weight from overweight Morgan Stanley said it sees a slowing recovery for the software company. Morgan Stanley reiterates General Motors as overweight Morgan Stanley said it's standing by the auto giant and that GM shares are "cheap." Mizuho reiterates Nvidia as buy Mizuho said it's standing by the stock heading into its GTC Conference in March. Morgan Stanley names Docebo a top pick Morgan Stanley named the ed-tech company a top pick. " Morgan Stanley reiterates Bloom Energy as overweight Morgan Stanley said the energy company is an "underappreciated AI winner."
Persons: Morgan Stanley downgrades ZoomInfo, Morgan Stanley, Oppenheimer, AAPL, it's, Mizuho, Goldman Sachs, Goldman, Redburn, Tesla, Daiwa, Jefferies, StoneCo, Wells, JPMorgan downgrades Lennox, LII, Docebo, Kraft Heinz, Mondelez, Kate McShane, Wolfe, Cash Organizations: OW, Apple, Motors, Nvidia, Conference, Citi, Qualcomm, Samsung, Deutsche Bank, Deutsche, Humana, Microsoft, Rockwell Automation, Rockwell, JPMorgan, UBS, SilverBow Resources, Regency, Kraft, Target, RBC downgrades New York Community Bancorp, RBC, New, Community Bancorp, Bloom Energy, Boston Scientific, Mizuho Locations: Boston
0 next >>
Total: 3